AsPC-1

AsPC-1 (Pancreatic Cancer CDX Model) 

The AsPC-1 pancreatic cancer cell line was derived from ascitic fluid of a patient with metastatic pancreatic adenocarcinoma. It represents aggressive pancreatic ductal adenocarcinoma (PDAC). AsPC-1 carries KRAS and TP53 mutations common in late-stage disease. Its aggressive phenotype makes it a valuable tool in pancreatic cancer research. 

Key Features: 

• Derived from metastatic pancreatic adenocarcinoma. 

• KRAS and TP53 mutations. 

• Aggressive, metastatic phenotype. 

• Epithelial morphology in culture. 

Applications: 
AsPC-1 is applied in studies of PDAC progression and therapy resistance. It is frequently used in drug screening and metastasis research. Researchers rely on it to evaluate chemotherapies and targeted agents in advanced pancreatic cancer. Its aggressive biology supports translational studies in late-stage PDAC.